Document:

<PAGE>

                                                                 EXHIBIT 10.22

                          InforMedix Acquisition Corp.
                                InforMedix, Inc.
                               5880 Hubbard Drive
                               Rockville, MD 20852
                                  301-984-1566
                                   301984-9096

                                October 16, 2003

Irving G. Snyder, Jr.
P.O. Box 367
45.32 State Road 14
Stevenson, WA 98684

Dear Irv:

         Reference is made to that certain (i) Security and Loan Agreement (the
"Loan Agreement") by and between InforMedix Acquisition Corp. (the "Company"),
InforMedix, Inc. ("IMI") and Irving G. Snyder, Jr. ("Snyder"); and (ii) Secured
Convertible Promissory Note (the "Note") in the principal amount of $750,000
issued by the Company and IMI to Snyder; each dated April 9, 2003 (the Loan
Agreement and Note are collectively referred to herein as the "Loan Documents").

         This is to confirm that the due date of the Note is hereby extended to
the earlier of (i) December 7, 2003 or (ii) the closing of the Placement (as
such term is defined below).

         This is to confirm that the Company and Snyder have agreed that at such
time as the Company sells shares of its capital stock or any securities
convertible into or exercisable for shares of its capital stock in a single
transaction or a series of substantially related transactions from which gross
proceeds of at least $2,000,000 are raised (herein referred to as the
"Placement"), then, Three Hundred Seventy Five Thousand Dollars ($375,000) of
the principal amount plus all accrued and unpaid interest under the Note, as of
the date of the initial closing of the Placement, shall, without any further
action on the part of the Holder, be repaid by the Company (the "Payment").

         The Company and Snyder further agree that the remaining balance of the
outstanding principal (which is Three Hundred Seventy Five Thousand Dollars
($375,000)), upon the closing of the Placement, will, without any further action
on the part of the Holder, be exchanged under the Terms and Conditions of the
Private Placement Memorandum for sales of Units of InforMedix Common Stock and
Warrants, into Units of the Private Placement as being sold by Meyers
Associates, which, if the Units are sold at $0.50 would result in Three Hundred
Seventy Five Thousand (375,000) units, consisting of 750,000 shares of Common
stock; 750,000 Class A Warrants exercisable for 750,000 shares of the Company's
Common Stock at $.60 per share and

<PAGE>

750,000 Class B Warrants exercisable for 375,000 shares of the Company's Common
Stock at $.75 per share (or $0.375 per Warrant) (the "Note Exchange").

         For purposes of illustrating the application of the previous paragraph
to a Placement where the Units are sold at less than $.50 per Unit, in the event
that the Units are sold are $.25 per Unit, the Note Exchange would result in the
issuance of Seven Hundred Fifty Thousand (750,000) units, consisting of
1,500,000 shares of Common stock; 1,500,000 Class A Warrants exercisable for
1,500,000 shares of the Company's Common Stock at $.30 per share and 1,500,000
Class B Warrants exercisable for 750,000 shares of the Company's Common Stock at
$.375 per share (or $0.1875 per Warrant).

         Upon execution of this letter agreement and delivery of the Note by
Snyder to the Company, an Amended and Restated Promissory Note will be issued by
the Company to Snyder which Amended and Restated Promissory Note will reflect
the terms of this letter agreement and will be substantially in the form of the
Note.

         The Company and Snyder hereby acknowledge and agree that the fair
market value of the consideration received as part of the Note Exchange (which
includes the shares of Common Stock, Class A Warrants and Class B Warrants
(collectively, the "Note Exchange Consideration")) shall not be less than an
amount equal to $375,000. In order to measure the fair market value of the Note
Exchange Consideration issued as part of the Note Exchange, the parties agree
that fair market value shall be equal to the daily average of the closing price
for the five (5) day period immediately after the shares are registered (the
"Measurement Period"). If the aggregate fair market value of the Note Exchange
Consideration is less than $375,000 at the end of the Measurement Period, then
the Company will pay the difference between the fair market value of the Note
Exchange Consideration and $375,000 by issuing additional registered common
shares to bring the value of the total number of shares and warrants issued to
$375,000.

         The Loan Documents, as modified hereby, will remain in effect until
such time as the Payment is made and the Note Exchange is completed as provided
above. At that time, Snyder agrees to terminate the Loan Agreement and his
related security interest in the Company's intellectual property as more fully
described in the Loan Agreements, and Snyder shall acknowledge that all
obligations of the Company to Snyder have been paid in full.

         In the event that the State of Washington requires that the shares of
Common Stock issued in connection with Note Exchange be registered with the
State of Washington in addition to the registration with the Securities and
Exchange Commission, the Company agrees to effect such filings as may be
required by the State Washington.

         Further reference is made to that certain (i) Warrant to Purchase
Shares of the Stock of InforMedix Acquisition Corp., issued to Springwater
Holdings, LLC whereby the holder may purchase up to 500,000 shares of the
Company's Common Stock at an exercise price of $1.50 per share; (ii) Warrant to
Purchase Shares of the Stock of InforMedix Acquisition Corp., issued to Snyder
whereby the holder may purchase up to 100,000 shares of the Company's Common
Stock at an exercise price of $1.50 per share; and (iii) Warrant to Purchase
Shares of the Stock of InforMedix Acquisition Corp., issued to Snyder whereby
the holder may purchase up to 1,000,000 shares of the Company's Common Stock at
an exercise price of $1.50 per share, each dated April 9, 2003 (these warrants
are collectively referred to as the "Snyder Warrants").

<PAGE>

         As a result of a reverse stock-split effectuated by the Company, the
Snyder Warrants are collectively exercisable for 800,000 shares of the Company's
Common Stock at an exercise price of $3.00 per share.

         As part of the transactions contemplated hereby, Snyder and the Company
have agreed that the Snyder Warrants will be surrendered by Snyder and
cancelled. As additional consideration for Snyder's agreements described above,
the Company has agreed to issue an additional warrant to Snyder whereby Snyder
will be entitled to purchase up to 250,000 shares of the Company's Common Stock
at an exercise price of $1.50 per share (the "Snyder Replacement Warrant"). The
Snyder Replacement Warrant will be in substantially the same form as the Snyder
Warrants and will be issued to Snyder (or his designees) upon execution of this
letter agreement and surrender of the Snyder Warrants to the Company.

         If the foregoing meets with your approval and reflects your
understanding of the terms and conditions of the matters referenced herein,
please so indicate by signing below. Upon execution by all signatories hereto
(which execution may be in counterparts), this letter agreement shall constitute
the legal and valid binding obligation of the parties.

                                      Yours sincerely,

                                      InforMedix Acquisition Corp.
                                      InforMedix, Inc.

                                      By: /s/ Bruce A. Kehr
                                        --------------------------------
                                         Bruce A. Kehr, M.D.
                                         Chairman and CEO

Accepted and Agreed:

   /s/Irving G. Snyder, Jr.
------------------------------------
Irving G. Snyder, Jr.EXHIBIT 10.23

                                INFORMEDIX, INC.
                             GEORGETOWNE OFFICE PARK
                               5880 HUBBARD DRIVE
                            ROCKVILLE, MD 20852-4821

   FAX: 301-984-9096                                       TEL: 301-984-1566

                                                                   Ref: 20030519
                                                                October 23, 2003

Arthur T. Healey
2508 Hunsberger Drive                                     Tel: 1-610-780-9251
Limerick, PA  19468                            eMail:  Art.Healey@InforMedix.com

                              EMPLOYMENT AGREEMENT

Dear Art:

         The purpose of this letter agreement (the "Agreement") is to confirm
the engagement of Employee, Art Healey ("Employee"), as an employee of
InforMedix, Inc. (the "Company") as Chief Financial Officer (CFO) and General
Counsel for InforMedix, Inc. It is the intent of each party to clarify the terms
of this Agreement in a more definitive agreement (the "Definitive Agreement") to
be drafted by Company's legal counsel. The following describes the Company's
business, and within this business, the responsibilities of the position of CFO
and General Counsel for InforMedix, Inc.

         InforMedix is a company that manufactures and will begin to market a
portable, patient-based, medical device that monitors patient medication
compliance, health status, and quality of life for clinical trials. The product
electronically links patients and healthcare professionals via an
Internet-accessible database to reduce the time-to-market for new drugs, improve
data integrity and patient safety in clinical trials, improve health outcomes
and reduce healthcare costs. The Mission of the company is "To Improve Patient
Medication Compliance for a Healthier World." The Company holds the pioneer
patent portfolio in this field.

1.         DUTIES

           A. This position reports to both the Chairman and CEO and the
President and COO. The CFO is also an officer of the corporation.

          The primary responsibilities as CFO are to: develop sales forecasts;
present to the investment community and shareholders on road shows and at annual
meetings, respectively; provide financial proforma modeling; develop relevant
financial statements for accounting purposes; provide liaison with any auditing
entities for purposes of financial reporting; support post-merger activities;
and to work with subcontractors for payroll, tax withholdings, accounts payable
and other matters relevant to the financial operations, and financial reporting
requirements of the Corporation. The CFO will work closely with sales and
marketing, R&D, manufacturing and customer service to develop divisional
budgets, and pricing models to support sales efforts.

                                                                      INFORMEDIX
                                                                     PAGE 1 OF 4

<PAGE>

         The CFO will work with the President and COO to determine the most
effective methods for cash use and management, such as the management of
inventory levels, parts, payments and the invoicing and receipt of cash to/from
customers. In addition, the CFO is responsible for dealing with all vendor
payments or payment methods to vendors with consideration of budget constraints
of the Corporation.

         From time to time, Mr. Healey will also interface with the Finance and
Audit Committee. He may be asked to work with this arm of the Board independent
of the management team to provide appropriate incentive compensation plan
information of competitive packages from companies of like or similar size;
and/or to create models and forecast to assist the Committee in its efforts.

         B. As General Counsel Employee shall perform the following:

               (1)  Assist the CEO and Chairman, President and COO, and Board of
                    Directors as needed in advising the Corporation on matters
                    of corporate law, and in negotiating various transactions;

               (2)  Draft Agreements and other legal documents on behalf of the
                    Corporation; and

               (3)  Supervise the work of the Company's outside legal counsel.

         C. Employee is expected to work effectively in an early-stage, fast
moving environment.

         D. Employee must be a successful team builder with the ability to
inspire and motivate others as the Corporation expands. The Employee's position
requires an individual that will thrive in an early-stage company culture, be
willing and able to work with the existing management team to build a strong
market presence.

2.       COMPENSATION AND BENEFITS

          A.   As compensation for Employee's services under this Agreement, the
               Company agrees to a salary of $150,000 paid in 24 equal
               installments. In addition, there will be a bonus of up to 20% of
               salary based upon achieving milestones, to be determined by the
               Compensation Committee of the Board of Directors.

          B.   Employee will be eligible to participate in the distribution of
               the Employee Bonus Pool established by the Compensation Committee
               of the Board.

          C.   Employee will receive an allowance for moving expenses of $20,000
               to be paid contemporaneously at the time the employee moves to
               the Rockville area .

          D.   Employee will receive the standard employee health benefit
               package including the ability to purchase family health benefits
               using pre-tax compensation dollars.

          E.   Employee will be issued stock options for a minimum of 112,500
               shares of InforMedix Holdings, Inc. common stock with an exercise
               price of $.50 per share to be the same as the PIPE price, said
               options vesting according to milestones established by the
               Compensation Committee. If the incentive option pool is adjusted
               through a stock split, reverse stock split,

                                                                      INFORMEDIX
                                                                     PAGE 2 OF 4
<PAGE>

               or other form of recapitalization, then Employee's number of
               options shall be ratably adjusted. Employee shall participate in
               increases in the stock option pool as determined by the
               Compensation Committee.

          F.   Employee shall continue to be reimbursed for travel expenses
               related to all business travel including weekly office commute as
               is the current practice.

          G.   Employee shall be entitled to a total of twenty-six (26) days of
               annual paid time off ("Annual PTO"), as defined below, during
               this Employment Agreement. Annual PTO days not used by the
               Employee during one twelve month period may be accrued and used
               during the next twelve (12) months. Annual PTO includes the
               following time taken off from work for the Corporation for any of
               the following reasons: vacations; national holidays; illness;
               personal use; or any other purpose not otherwise restricted or
               prohibited by this Employment Agreement.

3.       INTELLECTUAL PROPERTY

          A.   The Employee shall promptly disclose, grant and assign ownership
               to the Corporation for its sole use and benefit, any and all
               inventions, improvements, information, copyrights, trademarks,
               service marks, intellectual property, and suggestions (whether
               patentable or not), for devices and/or products that hold
               medication, and/or devices, products, and/or programs that
               provide medication, whose function is prompting for, and
               ascertaining medication compliance, and/or are portable
               technologies that are used by patients to capture data on
               medication compliance and/or health status, which Employee may
               develop, acquire, conceive or reduce to practice while employed
               by the Corporation (whether or not during usual working hours),
               together with all patent applications, letters patent,
               copyrights, trademarks, service marks, and other intellectual
               property (collectively "Intellectual Property"), and reissues
               thereof that may at any time be granted for or upon any such
               invention, improvement or information.

3.        TERM OF ENGAGEMENT

          A.   The three-year term of this Employment Agreement shall be
               effective July 1, 2003. Until such time Company receives funding
               of $1.5 million, Employee will receive half his compensation in
               the form of cash and half in the form of stock options. Employee
               will receive two options for each dollar of compensation deferred
               exercisable into one share of common stock each at $1.00 per
               share. Employee will begin to receive full compensation in cash
               when the Company receives equity funding of $1.5 million or more.
               This Agreement is an employment-at-will Agreement; however, if
               greater than 50% control of the Company is acquired by a
               strategic investor, all issued and unvested options accelerate
               and vest immediately.

          B.   Termination without Cause.

               Upon the termination of the Employee's employment under this
               Employment Agreement

                                                                      INFORMEDIX
                                                                     PAGE 3 OF 4
<PAGE>

               pursuant to Termination without Cause, neither the Employee nor
               the Employee's beneficiary or estate shall have any further
               rights or claims against the Corporation under this Employment
               Agreement, except to receive the following:

               (1)  The unpaid portion of the annual Salary computed on a pro
                    rata basis to the date of such termination; and,

               (2)  Reimbursement for any expenses for which the Employee shall
                    not have already been reimbursed; and,

               (3)  Payment of all unused vacation time accrued through the date
                    of termination; and,

               (4)  Salary, for the following number of months:

                    (a)  During the first year of this Employment Agreement -
                         two (2) months of Salary; plus,

                    (b)  One (1) additional month of Salary for each year of
                         employment for the Corporation beyond the first year,
                         to a maximum of a total of six (6) months of Salary.

               (5)  On the date of a Termination without Cause, all unvested
                    options, warrants, and other rights granted to the Employee
                    to purchase stock of the Corporation, shall immediately
                    vest.

4.       GENERAL PROVISIONS

          A.   This Agreement:

               (1)  Shall be contingent upon Employee resigning from and ending
                    any affiliation with BioMedical Development Group (except
                    for stock ownership); (2) Shall be governed by and construed
                    in accordance with the laws of the State of Maryland,
                    regardless of the laws that might otherwise govern under
                    applicable principles of conflicts of law thereof; (3)
                    Incorporates the entire understanding of the parties with
                    respect to the subject matter hereof and supersedes all
                    previous agreements should they exist with respect thereto
                    (except Company agrees that it will pay Employee $5,450 for
                    past services earned as an independent contractor upon the
                    closing of the first tranche in the Meyers Associates PIPE
                    transaction.; (4) May not be amended or modified except in a
                    writing executed by the Company and Employee; and

          B.   During the Term of Employment, the Employee shall not be engaged
               in any other business activity without the express written
               consent of the Corporation. Employee shall be entitled to wind
               down his business affairs with existing clients within a
               reasonable period of time. Such clients include the following:
               ParagonRx, LLC, and ProMetrics Consulting, Inc., and APA
               Transport Corporation.

                                                                      INFORMEDIX
                                                                     PAGE 4 OF 4
<PAGE>

          C.   This Agreement may be executed in two or more counterparts, each
               of which shall be deemed to be an original, but which together
               shall constitute one and the same Agreement.

         Please confirm that the foregoing is in accordance with your
understanding of our agreement by signing and returning to us an executed copy
of this letter.

                                              Very truly yours,
                                              INFORMEDIX, INC.

                                              BY: /s/ Bruce A. Kehr
                                                  -----------------------------
                                                  BRUCE A. KEHR, M.D.
                                                  CHAIRMAN AND CEO
ACCEPTED AND AGREED:

/s/ Art Healey
-------------------------------               ---------------------------------
ART HEALEY                                                DATE

                                                                      INFORMEDIX
                                                                     PAGE 5 OF 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}]]